Cancer Research The Future of Cancer Research: Science and Patient Impact  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 32, 1695-1702, August 1, 1972]
© 1972 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ash, R.
Right arrow Articles by Hellman, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ash, R.
Right arrow Articles by Hellman, S.

The Effects of Nitrogen Mustard on the Survival of Murine Hematopoietic Stem Cells1

Robert Ash, John T. Chaffey and Samuel Hellman

Department of Radiation Therapy, Harvard Medical School, Joint Center for Radiation Therapy, Boston, Massachusetts 02115

The effects of nitrogen mustard on murine hematopoietic stem cells are reported. The data indicate no evidence for intracellular repair of sublethal nitrogen mustard damage. The survival characteristics of cells at different positions of the cell cycle are different, with late S and G2 cells being most resistant, and G1 being most sensitive. The survival curve of hematopoietic stem cells can be resolved into a mixture of two populations of cells with different exponential survival characteristics. The sensitive population in great excess is probably due to the large proportion of cells either out of cycle or in a long G1 in this primarily resting population. The more resistant terminal slope can be explained by the small number of cells in the more resistant portion of the cycle (late S and G2). These data are then used to suggest ways of using HN2 alone or in combination with other agents to increase the therapeutic ratio.

1 Supported by USPHS Grant 5 R01-CA 10941.

Received 1/19/72. Accepted 4/24/72.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1972 by the American Association for Cancer Research.